Prevention of Mother to Child Transmission of HIV (PMTCT) during Antenatal Care

Last updated June 10, 2014
Case Authors: 
Alison C. Roxby, MD, MSc
Assistant Professor of Medicine
Division of Allergy and Infectious Diseases
University of Washington School of Medicine
Grace John-Stewart, MD, PhD
Professor Division of Infectious Diseases
Departments of Medicine, Epidemiology, Global Health, and Pediatrics
University of Washington School of Medicine
Christopher B. Behrens, MD
Clinical Associate Professor
Department sof Global Health and Medicine
University of Washington School of Medicine 
Learning Objectives: 
  1. Describe WHO guidelines for prevention of mother to child transmission of HIV.
  2. Understand effective therapies for reducing MTCT in resource-limited settings.

Display Group

  1. UNAIDS. Together we will end AIDS. Geneva, 2012.
  2. Lehman DA, Farquhar C. Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. Rev Med Virol. 2007;17:381-403.
  3. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. 2010 Version. Geneva, 2010.
  4. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis. 2000;183:206-212.
  5. Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: pathogenesis, mechanisms and pathways. Clin Perinatol. 2010;37:721-37, vii.
  6. WHO. Programmatic Update: Use of antiretroviral drugs for treating pregnant woman and preventing HIV infection in infants. 2012.
  7. WHO. Technical update on treatment optimization: Use of efavirenz during pregnancy: a public health perspective. Geneva, 2012.
  8. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25:2301-4.
  9. Bera E, McCausland K, Nonkwelo R, Mgudlwa B, Chacko S, Majeke B. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital. AIDS. 2010;24:283-9.
  10. Ouattara EN, Anglaret X, Wong AY, et al. Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS. 2012;26:625-34.
  11. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2010;:CD004246.
  12. Cain LE, Phillips A, Lodi S, et al. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS. 2012;26:1691-705.
  13. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772-6.
  14. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007;44:371-6.
  15. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26:1151-9.
  16. Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9:e1001217.
  17. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 2009;6:e1000172.
  18. Farr SL, Nelson JA, Ng'ombe TJ, et al. Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr. 2010;54:515-23.
  19. Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, et al. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. Clin Infect Dis. 2011;54:285-93.
  20. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009;48:462-72.
  21. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-47.
  22. Lockman S, McIntyre JA. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine. Lancet. 2007;370:1668-70.
  23. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS. 2007;21:957-64.
  24. Coffie PA, Ekouevi DK, Chaix ML, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis. 2008;46:611-21.
  25. Kuhn L, Semrau K, Ramachandran S, et al. Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2009;52:132-6.